Abstract 93P
Background
Real-world analyses of 1LM IO ± pemetrexed for patients (pts) with NSQ a/mNSCLC, including the relative impact of 1LM pemetrexed in this setting, are lacking. Here we report a retrospective analysis of 1LM treatment patterns and their outcomes in NSQ a/mNSCLC prior to/during the COVID-19 pandemic in the UK.
Methods
We obtained retrospective data from the National Disease Registration Service to identify two cohorts of NSQ a/mNSCLC completing ≥4 cycles of first-line (1L) platinum-based chemotherapy+IO+pemetrexed (chemo-IO), diagnosed from 1 March to 31 December 2019 (pre-COVID), or from 1 March to 31 December 2020 (COVID) inclusive. The aims were to summarise baseline characteristics, 1L treatment, overall survival (OS) and time-to-next-treatment or death (TTNTD) in both cohorts, and in a combined cohort of pts receiving 1LM stratified by the presence/absence of 1LM pemetrexed, using Kaplan-Meier methodology.
Results
595 and 516 NSQ a/mNSCLC pts completed ≥4 cycles of chemo-IO in the non-COVID and COVID cohorts, respectively. Median OS and median TTNTD from 1L were numerically shorter for NSQ patients in the COVID vs pre-COVID cohort (Table). In a combined cohort of 1000 pts receiving 1LM, median OS and median TTNTD from 1L were broadly similar with/without pemetrexed in 1LM (Table).
Table: 93P
Efficacy outcomes from initiation of 1L therapy
| Overall NSQ cohorts | Pre-COVID, N=595 | COVID, N=516 |
| Median OS, months (95% CI) | 19.5 (17.6–22.2) | 15.7 (14.2–18.0) |
| Median TTNTD, months (95% CI) | 14.8 (13.5–16.2) | 12.2 (11.0–13.7) |
| Pre-COVID and COVID combinedNSQ 1LM cohort, N=1000 | IO + pemetrexed, n=827 | IO, n=173 |
| Median OS, months (95% CI) | 19.5 (17.5–21.6) | 18.6 (15.6–23.0) |
| Median TTNTD, months (95% CI) | 15.0 (13.7–16.2) | 13.2 (11.7–16.3) |
Conclusions
Among the selected pts with NSQ a/mNSCLC completing ≥4 cycles of chemo-IO, efficacy outcomes were numerically shorter in the COVID vs pre-COVID era. In assessing impact of 1LM pemetrexed: clinical outcomes in a combined cohort of pts receiving 1LM from the non-COVID and COVID era were broadly similar, regardless of 1LM pemetrexed use.
Legal entity responsible for the study
GSK UK Limited.
Funding
GSK.
Disclosure
A.R. Minchom: Non-Financial Interests, Personal, Advisory Role: GSK; Financial Interests, Personal, Other, Grant/Contract:MSD, Astex; Financial Interests, Personal, Speaker’s Bureau: Merck, GSK, Janssen, Chugai, Seagen; Financial Interests, Personal, Sponsor/Funding: Amgen, Janssen; Financial Interests, Personal, Advisory Board: Janssen, GSK, Takeda, Genmab, Merck, MSD, Faron. N. Gilding, V. Tan, K. Christoforou, J. Rule, A. Aziez: Financial Interests, Personal, Full or part-time Employment: GSK. F. Gomes: Non-Financial Interests, Personal, Advisory Role: GSK; Financial Interests, Personal, Research Grant: Pfizer, Gilead; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Roche, Servier; Financial Interests, Personal, Sponsor/Funding, Travel sponsorship: AstraZeneca; Non-Financial Interests, Personal, Leadership Role: International Society of Geriatric Oncology. A. Januszewski: Non-Financial Interests, Personal, Advisory Role: GSK; Financial Interests, Personal, Research Grant: Gilead, Roche; Financial Interests, Personal, Other, Teaching: AstraZeneca, Johnson and Johnson, Roche, Pfizer, MSD, Bayer; Financial Interests, Personal, Sponsor/Funding, Travel sponsorship: Johnson and Johnson, Roche, MSD; Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Pfizer, MSD; Non-Financial Interests, Personal, Leadership Role, BTOG Steering Committee Member: British Thoracic Oncology Group.